Drug Type Autologous CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD276 inhibitors(CD276 antigen inhibitors), Gene transference(Gene transference) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Carcinoma | Phase 1 | United States | 13 Jul 2020 | |
Clear Cell Sarcoma | Phase 1 | United States | 13 Jul 2020 | |
Desmoplastic Small Round Cell Tumor | Phase 1 | United States | 13 Jul 2020 | |
Ewing Sarcoma | Phase 1 | United States | 13 Jul 2020 | |
Hepatoblastoma | Phase 1 | United States | 13 Jul 2020 | |
Melanoma | Phase 1 | United States | 13 Jul 2020 | |
Neuroblastoma | Phase 1 | United States | 13 Jul 2020 | |
Neurofibrosarcoma | Phase 1 | United States | 13 Jul 2020 | |
Retinoblastoma | Phase 1 | United States | 13 Jul 2020 | |
Rhabdoid Tumor | Phase 1 | United States | 13 Jul 2020 |
Phase 1 | 16 | tnzuacxfbw(uhvgmyiigw) = xgwrasigcf qsrcencjoh (fpgahoqubm ) View more | Positive | 02 Jun 2022 |